Cogent Biosciences, Inc.

NasdaqGS:COGT Stock Report

Market Cap: US$6.0b

Cogent Biosciences Management

Management criteria checks 4/4

Cogent Biosciences' CEO is Andy Robbins, appointed in Oct 2020, has a tenure of 5.5 years. total yearly compensation is $4.92M, comprised of 14.1% salary and 85.9% bonuses, including company stock and options. directly owns 0.29% of the company’s shares, worth $17.48M. The average tenure of the management team and the board of directors is 5.2 years and 5.8 years respectively.

Key information

Andy Robbins

Chief executive officer

US$4.9m

Total compensation

CEO salary percentage14.07%
CEO tenure5.5yrs
CEO ownership0.3%
Management average tenure5.2yrs
Board average tenure5.8yrs

Recent management updates

Recent updates

Cogent Biosciences: Time For A Pause

Dec 15

Cogent Biosciences: Buy The Pullback For Bezuclastinib's 2025 SM And GIST Data

Jan 18

Cogent Biosciences: Inflection Year Directly Ahead

Jun 23

Cogent Biosciences: Stock Soars On Cash Injection Ahead Of Major Data Catalyst

Feb 14

Cogent Biosciences: What's Ahead

Sep 13

Cogent Biosciences: APEX Data Was Interesting, But We Need More

Jun 26

CEO Compensation Analysis

How has Andy Robbins's remuneration changed compared to Cogent Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2025n/an/a

-US$329m

Sep 30 2025n/an/a

-US$294m

Jun 30 2025n/an/a

-US$284m

Mar 31 2025n/an/a

-US$269m

Dec 31 2024US$5mUS$692k

-US$256m

Sep 30 2024n/an/a

-US$242m

Jun 30 2024n/an/a

-US$227m

Mar 31 2024n/an/a

-US$212m

Dec 31 2023US$8mUS$656k

-US$192m

Sep 30 2023n/an/a

-US$178m

Jun 30 2023n/an/a

-US$157m

Mar 31 2023n/an/a

-US$148m

Dec 31 2022US$4mUS$624k

-US$140m

Sep 30 2022n/an/a

-US$126m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$91m

Dec 31 2021US$3mUS$593k

-US$72m

Sep 30 2021n/an/a

-US$163m

Jun 30 2021n/an/a

-US$194m

Mar 31 2021n/an/a

-US$185m

Dec 31 2020US$18mUS$102k

-US$179m

Compensation vs Market: Andy's total compensation ($USD4.92M) is below average for companies of similar size in the US market ($USD8.37M).

Compensation vs Earnings: Andy's compensation has been consistent with company performance over the past year.

CEO

Andy Robbins (49 yo)

5.5yrs
Tenure
US$4,917,890
Compensation

Mr. Andrew R. Robbins, also known as Andy, M.B.A., serves as Chief Executive Officer, President and Director of Cogent Biosciences, Inc. (formerly Unum Therapeutics Inc.) since October 23, 2020. He was a D...

Leadership Team

NamePositionTenureCompensationOwnership
Andrew Robbins
President5.5yrsUS$4.92m0.29%
$ 17.5m
John Green
CFO & Principal Accounting Officer5.8yrsUS$1.75m0.051%
$ 3.0m
John Robinson
Chief Scientific Officer5yrsUS$1.81m0.056%
$ 3.3m
Jessica Sachs
Chief Medical Officer6.8yrsUS$1.83m0.052%
$ 3.1m
Cole Pinnow
Chief Commercial Officer1.9yrsUS$3.97m0.10%
$ 6.2m
Brad Barnett
Chief Technology Officer5.4yrsno datano data
Christi Waarich
Senior Director of Investor Relationsno datano datano data
Evan Kearns
Chief Legal Officer & Corporate Secretary4.9yrsno data0.043%
$ 2.6m
Abb Hayden
Senior Vice President of Salesless than a yearno datano data
Erin Schellhammer
Chief People Officerno datano datano data
Dana Martin
Senior VP of Medical Affairs & Chief Patient Officerno datano datano data
Brad Fell
Senior Vice President of Chemistryno datano datano data
5.2yrs
Average Tenure
49.5yo
Average Age

Experienced Management: COGT's management team is seasoned and experienced (5.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Andrew Robbins
President5.5yrsUS$4.92m0.29%
$ 17.5m
Arlene Morris
Independent Director6.8yrsUS$359.56k0%
$ 0
Matthew Ros
Independent Director6.8yrsUS$349.56k0%
$ 0
Todd Shegog
Independent Director5.2yrsUS$362.06k0%
$ 0
Kwok-Kin Wong
Member of Scientific Advisory Boardno datano datano data
Karen Jean Ferrante
Independent Director8.2yrsUS$352.06k0%
$ 0
Michael Vasconcelles
Member of Scientific Advisory Boardno datano datano data
Ryan Corcoran
Member of Scientific Advisory Boardno datano datano data
Christopher Cain
Independent Director5.8yrsUS$357.06k0%
$ 0
Peter Harwin
Independent Chairman of the Board5.8yrsUS$382.06k0%
$ 0
Sylvia Adams
Member of Scientific Advisory Board3.3yrsno datano data
5.8yrs
Average Tenure
58.5yo
Average Age

Experienced Board: COGT's board of directors are considered experienced (5.8 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/21 05:45
End of Day Share Price 2026/04/21 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cogent Biosciences, Inc. is covered by 21 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Colleen KusyBaird
David LebowitzCitigroup Inc
Kelsey GoodwinGuggenheim Securities, LLC